Dassault Systemes SE (DSY.PAR) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 12 August 2026Deep analysis 5 July 202625 min read

Audit All Past Forecasts

12 AI Advisor Reports

Select an advisor report.

Niccolo Machiavelli AI

The Insider FrameworkAI Researcher

Rating

Strong Buy

5-Year Return Est.

+140.6%

DSY.PAR does not currently pay dividends

1. Investment Thesis — Base Case

DSY is currently priced for perpetual stagnation, offering an asymmetric entry point into a state-backed monopoly. The stock will slowly compound its way out of the Q1 2026 penalty box as ARR visibility improves and European defense spending physically materializes in software bookings. The market fundamentally ignores the durability of DSY's political protection in France and Brussels. Medidata growth will re-accelerate as Chinese CDMO decoupling forces Western pharma to standardize on trusted systems. Defense and aerospace lock-ins provide a rigid revenue floor that offsets European auto weakness. The 19.6x multiple will gradually expand back to a historically reasonable 25-28x as 2027/2028 margin expansion proves the subscription model is structurally more profitable than perpetual licenses.

Market ignores the durability of DSY's political protection in France and Brussels.
Medidata growth re-accelerates as Chinese decoupling forces Western pharma to standardize on trusted systems.
Defense and aerospace provide a rigid revenue floor that offsets European auto weakness.
The 19.6x multiple gradually expands back to a historically reasonable 25-28x.
2027/2028 proves the subscription model works.

Interactive forecast chart

Figure: Five-year interactive consensus forecast for Dassault Systemes, including the advisor-disagreement range and benchmark comparison. Sign in, verify your email, and use the required subscription to explore the chart.

AI Advisor 1

Niccolo Machiavelli

Rating: strong_buy
Forecasted compounded return: +140.6%
Forecast anchor: 18.50 EUR on July 3, 2026

Most reasonable investment thesis

DSY is currently priced for perpetual stagnation, offering an asymmetric entry point into a state-backed monopoly. The stock will slowly compound its way out of the Q1 2026 penalty box as ARR visibility improves and European defense spending physically materializes in software bookings. The market fundamentally ignores the durability of DSY's political protection in France and Brussels. Medidata growth will re-accelerate as Chinese CDMO decoupling forces Western pharma to standardize on trusted systems. Defense and aerospace lock-ins provide a rigid revenue floor that offsets European auto weakness. The 19.6x multiple will gradually expand back to a historically reasonable 25-28x as 2027/2028 margin expansion proves the subscription model is structurally more profitable than perpetual licenses. - Market ignores the durability of DSY's political protection in France and Brussels. - Medidata growth re-accelerates as Chinese CDMO decoupling forces Western pharma to standardize on trusted systems. - Defense and aerospace provide a rigid revenue floor that offsets European auto weakness. - The 19.6x multiple gradually expands back to a historically reasonable 25-28x. - 2027/2028 margin expansion proves the subscription model works.

Bull case

The EU structurally weaponizes its tech procurement, locking US hyperscalers out of critical defense and medical data. DSY realizes the full power premium of its captive market, triggering aggressive multiple expansion. - DSY's Outscale becomes the de facto European sovereign cloud. - US legacy reshoring drives record SOLIDWORKS adoption. - Pascal Daloz executes a flawless ARR transition, restoring EPS growth to mid-teens.

Bear case

European stagflation deepens into a severe industrial recession, freezing CAPEX across auto and aerospace while the subscription transition fails to gain traction. The political moat is breached by US lobbying. - Customers refuse the subscription transition, retaining legacy perpetual licenses. - US tech giants successfully lobby Brussels to dilute sovereign cloud definitions. - The Dassault family refuses to optimize capital structure, creating a permanent value trap.

Sentiment and regime

Greed and fear sentiment: -0.7
Expected volatility regime: moderate
Convergence-cycle position: stabilization

Broader narrative

Current crowd consensus: The crowd views Dassault Systemes as a broken European software story, anchored by the disastrous Q4 2025 earnings and pathetic 3-5% guidance for 2026. Sell-side analysts fret over stagnant auto-sector CAPEX, Medidata CRO delays, and the clumsy transition to ARR reporting. The media obsesses over Bernard Charles stepping down, assuming elevated leadership execution risk. They are pricing this asset as a generic SaaS vendor fighting for discretionary IT budgets, justifying the 15-year low P/E multiple of 19.6x.
Alpha-gap assessment: The variant perception is that the crowd confuses temporary subscription-transition friction with structural power erosion. DSY is not a discretionary SaaS vendor; it is the digital twin of the European military-industrial complex. While analysts panic over cyclical auto weakness, the Dassault empire is busy writing European procurement law (CADA, SecNumCloud) to mandate its Outscale cloud for sovereign defense projects. The Alpha Gap is the chasm between a 19x multiple pricing in perpetual stagnation and a legally enforced monopoly capturing the incoming wave of European remilitarization and biotech reshoring.
Convergence catalyst: The formalization of binding European Commission 'tech sovereignty' mandates requiring EU-certified cloud infrastructure for defense and critical data, combined with Medidata securing massive Western pharma contracts driven by BIOSECURE decoupling. This regulatory guillotine will force the market to reprice DSY as sovereign critical infrastructure rather than cyclical software by mid-2027.
Macro-regime alignment: The Warsh Fed's higher-for-longer rate regime violently penalizes unprofitable tech but provides a massive premium for asset-light, 84% gross margin cash compounders. Furthermore, the global shift toward geopolitical fragmentation and supply-chain reshoring acts as a direct structural tailwind, as duplicate Western industrial bases require duplicate digital twin software licenses.

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
EU Sovereign Cloud Mandates	Dassault is aggressively lobbying the European Commission via the EuroStack initiative and ESTIA to funnel public procurement toward 'sovereign' European cloud infrastructure. Upcoming legislation (CADA) and SecNumCloud certifications act as a regulatory guillotine for US hyperscalers in sensitive sectors, legally ensuring that DSY's Outscale and 3DEXPERIENCE platforms capture the captive demand from European defense, government, and aerospace primes. This is textbook regulatory capture establishing a rigid revenue floor.	Not available%	+35.0%
Biosecure Biotech Decoupling	Western decoupling from Chinese CDMOs/CROs forces a massive geographic re-platforming of clinical trials. DSY's Medidata subsidiary holds the gold standard for Western clinical trial SaaS. As pharma companies rip out compromised Chinese data infrastructure to comply with new geopolitical boundaries, Medidata captures this forced reshoring wave. The market currently prices Medidata on past CRO slowdowns, entirely ignoring this legally mandated geopolitical migration.	Not available%	+25.0%
Defense Industrial Consolidation	European remilitarization and rigid NATO burden-sharing targets require seamless digital integration across fragmented national contractors. DSY's CATIA and PLM suites are the non-substitutable digital architecture for European combat systems. As expanding defense budgets finally convert into physical manufacturing pipelines, DSY effortlessly extracts a toll on every digital twin constructed, entirely insulated from civilian economic cycles.	Not available%	+20.0%
Legacy Industry Reshoring	The repeal of the US EPA Endangerment Finding and broad industrial deregulation unleashes heavy manufacturing and legacy auto capex in North America. Building physical infrastructure requires virtual testing. DSY's SOLIDWORKS and SIMULIA are perfectly positioned to tax this manufacturing renaissance. This creates a dual-continent protection scheme: sovereign defense in Europe, and deregulated industrial expansion in the US.	Not available%	+15.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Automotive Sector Stagflation	European automotive manufacturing is suffering from structural stagnation, compounded by the Hormuz energy shock and fierce Chinese EV market penetration. Since the automotive sector is a major end-market for DSY's PLM software, capital expenditure freezes by Tier 1 suppliers act as a persistent drag on license growth and recurring revenue conversion, clouding short-term earnings visibility.	Not available%	-15.0%
Private AI Compute Squeeze	The global AI infrastructure bottleneck surrounding power, memory, and advanced packaging raises the base cost of compute. DSY's ambitions to deploy 'Industry World Models' and generative virtual twins require massive capital outlays for sovereign inference infrastructure. This dynamic threatens to temporarily compress gross margins as the hyperscaler capex tax is passed down to application-layer SaaS platforms.	Not available%	-12.0%
Management Transition Execution	Bernard Charles stepped down in early 2026 after 40 years of defining the company's DNA, leaving Pascal Daloz in charge under the absolute control of the Dassault family. This transition creates execution risk during a delicate shift to subscription-based ARR reporting, alienating institutional investors who demand transparent quarterly linearity over dynastic succession.	Not available%	-10.0%
DUAL Class Minority Squeeze	The Groupe Industriel Marcel Dassault effectively controls the board. Minority shareholders are merely passengers providing liquidity. In a regime of expensive capital, international funds apply a governance discount to family fiefdoms that prioritize state-aligned industrial strategy and political moats over aggressive share buybacks and short-term dividend maximization, capping the valuation multiple.	Not available%	-8.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
PAN European Defense Cloud Procurement	The EU Commission formally mandates that all cross-border European defense projects must be designed and hosted exclusively on certified sovereign European cloud architecture. DSY's Outscale immediately becomes the monopoly infrastructure, triggering an upward rerating of its cloud revenue projections and permanently locking out US competitors.	45.0%	+18.0%
Medidata AI DATA Monetization	Medidata successfully commercializes its Clinical Data Studio by training proprietary AI models on its unparalleled repository of historical clinical trial data, transitioning from a pure workflow SaaS to a predictive algorithmic drug-discovery partner. This validates DSY's AI narrative and closes the valuation gap with high-multiple US health-tech names.	35.0%	+15.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
SAAS Subscription Deflation	Industrial customers, squeezed by the Hormuz energy shock and regional stagflation, aggressively push back against DSY's forced transition to subscription (ARR) models. Seat counts contract and downgrade cycles accelerate, causing DSY to miss its already lowered 2026 revenue guidance of 3-5%, triggering a final institutional capitulation.	40.0%	-25.0%
Sovereign Cloud Compromise	The European Commission bows to immense pressure from US tech lobbying and dilutes the 'sovereignty' criteria in CADA, allowing US hyperscalers to dominate European public sector and defense contracts via shallow joint ventures. DSY's political moat breaches, exposing its higher-cost cloud offerings to lethal price competition.	30.0%	-20.0%

Step-by-step forecast path

Niccolo Machiavelli forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_c58baba5-f765-54bd-a102-754b5b1ba084__sb6__20260705144805
Step	Forecast date	Step change	Projected value (EUR)	Scenario rationale
1	October 3, 2026	+5.0%	19.43	Selling exhaustion post-crash allows for a relief rally. Q3 metrics show initial stabilization in the ARR transition and a life-sciences floor, bringing value buyers off the sidelines.
2	January 3, 2027	+8.0%	20.98	Full-year 2026 results confirm the lowered 3-5% guidance was met, eliminating the catastrophic tail-risk priced in by the February gap down and forcing short covering.
3	April 3, 2027	+5.0%	22.03	BIOSECURE execution accelerates pharma shifts away from China; Medidata logs accelerating bookings as CROs standardize on trusted Western SaaS environments.
4	July 3, 2027	+3.0%	22.69	EU Commission formalizes tech-sovereignty mandates; DSY's Outscale platform captures structural European defense and government procurement, supporting a steady summer advance.
5	October 3, 2027	+6.0%	24.05	Capital Markets Day re-establishes medium-term margin targets; the market regains confidence in Pascal Daloz's leadership outside Bernard Charles' shadow.
6	January 3, 2028	+7.0%	25.73	Operating leverage forcefully kicks in as subscription renewals compound without heavy new acquisition costs; net margin expands past 20%, driving multiple expansion.
7	April 3, 2028	+4.0%	26.76	Legacy heavy industry in the US, buoyed by deep deregulation, completes digital-twin integration, driving solid growth in SOLIDWORKS outside the European core.
8	July 3, 2028	+5.0%	28.10	Pan-European defense spending converts into physical manufacturing pipelines, driving locked-in CATIA seat expansions among allied aerospace and defense primes.
9	October 3, 2028	+2.0%	28.66	The P/E multiple successfully normalizes from the sub-20x trough to the mid-20s, reflecting the return of predictable double-digit EPS growth; price action consolidates.
10	January 3, 2029	+6.0%	30.38	AI monetization directly hits the income statement as Clinical Data Studio upselling deeply penetrates the core life-sciences client base, expanding total contract value.
11	April 3, 2029	+4.0%	31.60	A stabilizing European macro environment finally unfreezes automotive sector R&D budgets, adding a cyclical tailwind to the established structural growth.
12	July 3, 2029	+3.0%	32.55	Geopolitical fragmentation permanently cements DSY as the non-substitutable digital infrastructure for the Western and allied industrial base. Stable, low-volatility drift upwards.
13	October 3, 2029	+5.0%	34.17	Persistent high-rate macro environment forces institutional capital out of speculative tech and toward asset-light cash compounders; DSY benefits from index reallocations.
14	January 3, 2030	+6.0%	36.22	Robust free cash flow supports aggressive dividend hikes and share repurchases, heavily rewarding the patient Dassault family governance structure and minority co-investors.
15	April 3, 2030	+3.0%	37.31	Integration of next-generation AI into 3DEXPERIENCE allows automated generative design, expanding the TAM into lower-tier manufacturing that previously lacked engineering talent.
16	July 3, 2030	+4.0%	38.80	The stable recurring revenue base acts as a massive shock absorber against late-cycle economic wobbles, preserving the premium multiple during broader market turbulence.
17	October 3, 2030	+2.0%	39.58	Medidata solidifies absolute dominance in global clinical trial management as global data-privacy barriers make unified, sovereign-compliant platforms mandatory.
18	January 3, 2031	+5.0%	41.56	Decades of aerospace lock-in translate to zero churn as next-generation space-launch and orbital manufacturing projects standardize entirely on DSY software.
19	April 3, 2031	+4.0%	43.22	Steady compounding continues; the underlying moat remains fiercely protected by unparalleled switching costs in mission-critical hardware design workflows.
20	July 3, 2031	+3.0%	44.52	The ultimate vindication of the Insider thesis: political protection, monopoly mechanics, and regulatory capture deliver a sustained, multi-year compounding run from the 2026 panic trough.

Advisor and configuration

Advisor: machiavelli__the_insider__google_gemini_3_1_pro__20260201_preview_release
Persona: Niccolo Machiavelli
Archetype: The Insider
Model: (February 01, 2026) Preview Release
Provider: Google
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: machiavelli__the_insider__google_gemini_3_1_pro__20260201_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: machiavelli__the_insider__google_gemini_3_1_pro__20260201_preview_release RESEARCHER Forecast Assembly
Input format: Latest Close Price with Stats and Fundamentals
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Machiavelli advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check access View Base plan Return to latest AI Consensus